IL-6 can impair Th1 differentiation through stimulating IL-4/IL-21 production and therefore has negative impacts on antitumor responses by shifting Th1/Th2 balance to Th2 dominance [21], leading to unfavorable prognosis in a wide range of tumor types including gastric cancer. Here, IL21 is linked to neoplasm.